SRD5A1and SRD5A2are Associated with the Treatment for Benign Prostatic Hyperplasia with the Combination of 5α-reductase Inhibitors and α-adrenergic-receptor Antagonist

Abstract

Introduction & Objectives

5α-reductase inhibitors and α-adrenergic-receptor antagonists are commonly used treatments for benign prostatic hyperplasia (BPH). However, these treatments can only partially reduce the risk of BPH progression. SRD5A1 and SRD5A2 are targets for 5α-reductase inhibitors. Our objective was to investigate the association between drug efficacy and single nucleotide polymorphisms (SNPs) in the SRD5A1 and SRD5A2 genes in a Chinese population.

Materials & Methods

Eleven tagging SNPs (tSNPs) in the SRD5A1 and SRD5A2 genes were genotyped in 426 BPH cases and 1,008 controls from Xinhua Hospital in Shanghai, China. Cases were treated by Type II 5α-reductase inhibitors and α-adrenergic-receptor antagonists. Association between tSNPs, BPH risk/progressiveness, clinical characteristics at baseline, including International Prostate Symptom Score (IPSS) and total prostate volume (TPV), and changes in clinical characteristics after treatment were tested.

Results

The 11 tSNPs were not significantly associated with BPH risk or progressiveness (All P>0.05). rs6884552 and rs3797177 in the SRD5A1 gene, were significantly associated with IPSS score at baseline with a P-value of 0.04 and 0.003, respectively. rs523349 (V89L) and rs9332975 in the SRD5A2 gene were significantly associated with TPV at baseline (P=0.01 and 0.001 respectively). rs166050 in SRD5A1 was significantly associated with the change of TPV after treatment (P=0.04). rs523349 and rs612224 in SRD5A2 were significantly associated with the change of IPSS after treatment (P=0.03 and 0.009, respectively).

Conclusions

SNPs in SRD5A1 and SRD5A2 were significantly associated with clinical characteristics of BPH and efficacy of BPH treatment.

http://www.jurology.com/article/S0022-5347(13)03659-8/abstract